Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.41 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21831249 | 1.00 | SLC6A4 (0.45) | SLC6A4GPR139SLC6A2CETPHDAC8 | |
| SCHEMBL1047408 | 0.86 | SLC6A4 (0.45) | SLC6A4GPR139SLC6A2HDAC8CHRM2 | |
| SCHEMBL2662566 | 0.85 | KDM4E (0.45) | SLC6A4GPR139SLC6A2CETPHDAC8 | |
| SCHEMBL19368153 | 0.82 | SLC6A4 (0.43) | SLC6A4GPR139SLC6A2CETPHDAC8 | |
| SCHEMBL1727565 | 0.82 | SLC6A2 (0.43) | SLC6A4GPR139SLC6A2 | |
| SCHEMBL14536898 | 0.82 | CETP (0.46) | SLC6A4GPR139SLC6A2CETPHDAC8 | |
| SCHEMBL1047410 | 0.82 | CETP (0.46) | SLC6A4GPR139SLC6A2CETPHDAC8 | |
| SCHEMBL2715618 | 0.82 | SLC6A2 (0.43) | SLC6A4GPR139SLC6A2 | |
| SCHEMBL16959753 | 0.82 | SLC6A4 (0.43) | SLC6A4GPR139SLC6A2CETPHDAC8 | |
| SCHEMBL19121488 | 0.82 | SLC6A4 (0.43) | SLC6A4GPR139SLC6A2CETPHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| WO-2022116998-A1 | FUSED HETEROCYCLIC DERIVATIVES AS HBV INHIBITORS | Janssen Sciences Ireland Unlimited Company (IE) | 2022-06-09 | — | — | WO | disclosed |